

David Alan Schoenfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113809/publications.pdf>

Version: 2024-02-01

93
papers

7,505
citations

81839

39
h-index

56687

83
g-index

94
all docs

94
docs citations

94
times ranked

10134
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Cerebral Edema in Substance-Related Cardiac Arrest Patients. Resuscitation, 2022, , .	1.3	2
2	Impact of GH administration on skeletal endpoints in adults with overweight/obesity. European Journal of Endocrinology, 2022, 186, 619-629.	1.9	2
3	Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults. JAMA Network Open, 2022, 5, e222106.	2.8	34
4	Long-term survival of participants in the <sc>CENTAUR</sc> trial of sodium phenylbutyrate–taurursodiol in <sc>amyotrophic lateral sclerosis</sc>. Muscle and Nerve, 2021, 63, 31-39.	1.0	115
5	Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1330-1344.	2.2	22
6	Predictors and moderators of symptom change during cognitive-behavioral therapy or supportive psychotherapy for body dysmorphic disorder. Journal of Affective Disorders, 2021, 287, 34-40.	2.0	13
7	Sequential Therapy With Recombinant Human IGF-1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2021, 36, 2116-2126.	3.1	9
8	Estimation for an accelerated failure time model with intermediate states as auxiliary information. Lifetime Data Analysis, 2020, 26, 1-20.	0.4	4
9	Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence. Journal of Psychopharmacology, 2020, 34, 197-210.	2.0	10
10	Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930.	13.9	299
11	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2165.	3.8	352
12	Prospective Assessment of the Feasibility of a Trial of Low Tidal Volume Ventilation for Patients with Acute Respiratory Failure. Annals of the American Thoracic Society, 2019, 16, 356-362.	1.5	20
13	Design and analysis of a clinical trial using previous trials as historical control. Clinical Trials, 2019, 16, 531-538.	0.7	11
14	S54. INTEGRATED DIABETES MANAGEMENT FOR INDIVIDUALS WITH SERIOUS MENTAL ILLNESS (SMI). Schizophrenia Bulletin, 2019, 45, S327-S327.	2.3	0
15	A Randomized Placebo-Controlled Trial of Low-Dose Testosterone Therapy in Women With Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4347-4355.	1.8	14
16	Editorial: We may need large trials to find treatments for neurodegenerative diseases. Clinical Trials, 2019, 16, 120-121.	0.7	0
17	Reappraisal of Ventilator-Free Days in Critical Care Research. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 828-836.	2.5	210
18	A commentary on: statistical inference problems in sequential parallel comparison designs. Journal of Biopharmaceutical Statistics, 2019, 29, 1130-1133.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 363.	6.0	64
20	A pilot trial of RNS60 in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2019, 59, 303-308.	1.0	29
21	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS. <i>Neurology</i> , 2018, 90, e565-e574.	1.5	99
22	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 242-249.	1.1	35
23	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. <i>Muscle and Nerve</i> , 2018, 57, 430-434.	1.0	39
24	A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 250-258.	1.1	44
25	Informatively clustering longitudinal microarrays using binary or survival outcome data. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2018, 4, 18-27.	0.3	0
26	Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. <i>Neurotherapeutics</i> , 2017, 14, 762-772.	2.1	73
27	Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 1137-1138.	4.9	1
28	Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. <i>Addictive Behaviors</i> , 2017, 71, 89-95.	1.7	11
29	Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. <i>Neurology</i> , 2017, 89, 1483-1489.	1.5	18
30	Relationship between Race and the Effect of Fluids on Long-term Mortality after Acute Respiratory Distress Syndrome. Secondary Analysis of the National Heart, Lung, and Blood Institute Fluid and Catheter Treatment Trial. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1443-1449.	1.5	13
31	Power Calculations to Select Instruments for Clinical Trial Secondary Endpoints. A Case Study of Instrument Selection for Post-Traumatic Stress Symptoms in Subjects with Acute Respiratory Distress Syndrome. <i>Annals of the American Thoracic Society</i> , 2017, 14, 110-117.	1.5	6
32	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). <i>Journal of Neurology & Neurophysiology</i> , 2017, 08, .	0.1	17
33	Longitudinal immunological characterization of the first presensitized recipient of a face transplant. <i>JCI Insight</i> , 2017, 2, .	2.3	18
34	Remote video auditing with real-time feedback in an academic surgical suite improves safety and efficiency metrics: a cluster randomised study. <i>BMJ Quality and Safety</i> , 2016, 25, 947-953.	1.8	30
35	Coronary CT Angiography Versus Standard Emergency Department Evaluation for Acute Chest Pain and Diabetic Patients: Is There Benefit With Early Coronary CT Angiography?. <i>Journal of the American Heart Association</i> , 2016, 5, e003137.	1.6	20
36	Reply to Phillips, Morris, and Walker. <i>Clinical Infectious Diseases</i> , 2016, 62, 815-816.	2.9	5

#	ARTICLE	IF	CITATIONS
37	Quantitative strength testing in ALS clinical trials. <i>Neurology</i> , 2016, 87, 617-624.	1.5	37
38	Assessing survival benefit when treatment delays disease progression. <i>Clinical Trials</i> , 2016, 13, 352-357.	0.7	5
39	A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. <i>Nature Nanotechnology</i> , 2016, 11, 378-387.	15.6	201
40	Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome. <i>Chest</i> , 2016, 150, 307-313.	0.4	127
41	How common are ALS plateaus and reversals?. <i>Neurology</i> , 2016, 86, 808-812.	1.5	78
42	Induced regulatory T cells in allograft tolerance via transient mixed chimerism. <i>JCI Insight</i> , 2016, 1, .	2.3	40
43	Reply. <i>Muscle and Nerve</i> , 2015, 52, 691-691.	1.0	2
44	Preâ€morbidity type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 52, 339-343.	1.0	25
45	Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging. <i>Theranostics</i> , 2015, 5, 289-301.	4.6	154
46	Outcome-Driven Cluster Analysis with Application to Microarray Data. <i>PLoS ONE</i> , 2015, 10, e0141874.	1.1	6
47	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. <i>Nature Biotechnology</i> , 2015, 33, 51-57.	9.4	178
48	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). <i>Clinical Infectious Diseases</i> , 2015, 61, 800-806.	2.9	206
49	Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. <i>American Heart Journal</i> , 2015, 169, 572-578.e1.	1.2	23
50	Use of Coronary Artery Calcium Scanning Beyond Coronary Computed Tomographic Angiography in the Emergency Department Evaluation for Acute Chest Pain. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	44
51	The PRO-ACT database. <i>Neurology</i> , 2014, 83, 1719-1725.	1.5	222
52	Preventing ARDS. <i>Chest</i> , 2014, 146, 1102-1113.	0.4	47
53	Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy nduced clinical erythema. <i>Journal of Biomedical Optics</i> , 2014, 19, 028001.	1.4	46
54	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , 2014, 11, 494-502.	0.7	9

#	ARTICLE	IF	CITATIONS
55	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	2.0	18
56	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 1083-1091.	4.9	187
57	Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia. <i>Human Pathology</i> , 2014, 45, 342-351.	1.1	47
58	A test for the relationship between a time-varying marker and both recovery and progression with missing data. <i>Statistics in Medicine</i> , 2011, 30, 718-724.	0.8	3
59	Bayesian design using adult data to augment pediatric trials. <i>Clinical Trials</i> , 2009, 6, 297-304.	0.7	61
60	The natural history of ALS is changing: Improved survival. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 324-331.	2.3	66
61	Design of phase II ALS clinical trials. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 16-23.	2.3	34
62	Trial of celecoxib in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2006, 60, 22-31.	2.8	276
63	Calculating the power or sample size for the logistic and proportional hazards models. <i>Journal of Statistical Computation and Simulation</i> , 2005, 75, 771-785.	0.7	22
64	Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. <i>Critical Care</i> , 2005, 10, 103.	2.5	52
65	Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments. <i>Critical Care</i> , 2004, 9, 34.	2.5	26
66	Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. <i>Critical Care Medicine</i> , 2002, 30, 1772-1777.	0.4	462
67	Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 599-603.	1.8	155
68	Metabolism of Orally Administered Androstenedione in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3654-3658.	1.8	36
69	Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. <i>Clinical Endocrinology</i> , 2001, 54, 183-188.	1.2	76
70	Low bone mineral density in hormone-naïve men with prostate carcinoma. <i>Cancer</i> , 2001, 91, 2238-2245.	2.0	130
71	Nonparametric Estimation in a Cure Model with Random Cure Times. <i>Biometrics</i> , 2001, 57, 282-286.	0.8	37
72	A Simple Algorithm for Designing Group Sequential Clinical Trials. <i>Biometrics</i> , 2001, 57, 972-974.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Efficacy of Low Tidal Volume Ventilation in Patients with Different Clinical Risk Factors for Acute Lung Injury and the Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 231-236.	2.5	281
74	Low bone mineral density in hormone-negative men with prostate carcinoma. Cancer, 2001, 91, 2238-2245.	2.0	1
75	Metabolism of Orally Administered Androstenedione in Young Men. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3654-3658.	1.8	17
76	The selective muscarinic M1 agonist AF102B decreases levels of total A β in cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology, 2000, 48, 913-918.	2.8	150
77	A model for markers and latent health status. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2000, 62, 747-762.	1.1	40
78	Withdrawal of Long-Term Physiological Growth Hormone (GH) Administration: Differential Effects on Bone Density and Body Composition in Men with Adult-Onset GH Deficiency*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 970-976.	1.8	92
79	Combining mortality and longitudinal measures in clinical trials. , 1999, 18, 1341-1354.		225
80	Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome. Antiviral Therapy, 1998, 3, 25-32.	0.6	15
81	Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2248-2256.	1.8	355
82	A Random-Effects Model for Multiple Characteristics with Possibly Missing Data. Journal of the American Statistical Association, 1997, 92, 775-779.	1.8	131
83	ANALYSIS OF MULTIPLE FAILURE TIME DATA FROM AN AIDS CLINICAL TRIAL. Statistics in Medicine, 1997, 16, 951-961.	0.8	17
84	A Random-Effects Model for Multiple Characteristics With Possibly Missing Data. Journal of the American Statistical Association, 1997, 92, 775.	1.8	25
85	LONG-TERM FOLLOW-UP IN AIDS CLINICAL TRIALS. , 1996, 15, 2359-2366.		1
86	Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. Journal of Bone and Mineral Research, 1996, 11, 430-439.	3.1	43
87	Suppression by the sumatriptan analogue, CPâ€12,288 of câ€fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. British Journal of Pharmacology, 1995, 114, 987-992.	2.7	32
88	Analysing survival in the presence of an auxiliary variable. Statistics in Medicine, 1994, 13, 1747-1754.	0.8	51
89	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. Brain Pathology, 1993, 3, 19-26.	2.1	597
90	Design Considerations for AIDS Trials. New England Journal of Medicine, 1990, 323, 1343-1348.	13.9	149

#	ARTICLE	IF	CITATIONS
91	Confidence Bounds for Normal Means under Order Restrictions, with Application to Dose-Response Curves, Toxicology Experiments, and Low-Dose Extrapolation. Journal of the American Statistical Association, 1986, 81, 186-195.	1.8	42
92	Confidence Bounds for Normal Means Under Order Restrictions, With Application to Dose-Response Curves, Toxicology Experiments, and Low-Dose Extrapolation. Journal of the American Statistical Association, 1986, 81, 186.	1.8	5
93	The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika, 1981, 68, 316-319.	1.3	436